Veeva Systems Q3 guidance beats estimates on EPS, sales

0 min read | Published on 27 Aug 2026, 02:07 AM |Updated on 27 Aug 2026, 02:07 AM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

Key Highlights

Veeva Systems forecasts Q3 adjusted EPS of $2.33-$2.34 vs $2.28 estimate
Projected sales range from $932 million to $935 million vs $918.074 million estimate
Both earnings and revenue guidance exceed analyst consensus expectations

*this image is generated using AI for illustrative purposes only.

Veeva Systems (NYSE: VEEV) projected third-quarter adjusted earnings per share (EPS) between $2.33 and $2.34, exceeding the analyst consensus estimate of $2.28. The cloud-based software company also forecast sales in the range of $932 million to $935 million, beating the expected revenue of $918.074 million.

Financial Outlook

The company’s guidance indicates a positive deviation from market expectations across both profitability and top-line growth metrics for the quarter.

Metric	Guidance Range	Analyst Estimate	Variance
Adjusted EPS	$2.33 - $2.34	$2.28	Beat
Sales	$932.000M - $935.000M	$918.074M	Beat

What the Numbers Show

The upper bound of the adjusted EPS guidance ($2.34) represents a 2.6% premium over the analyst estimate ($2.28). Similarly, the lower bound of the sales forecast ($932 million) exceeds the revenue estimate by approximately 1.5%, suggesting broad-based confidence in both volume and margin performance for the period.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

Will Veeva Systems' ability to beat earnings and revenue estimates trigger an upward revision in its full-year 2024 guidance?

How might this positive performance impact Veeva's valuation multiples relative to other cloud-based healthcare software competitors?

What specific product segments or geographic regions are driving the stronger-than-expected sales volume, and are these trends sustainable?

Veeva Systems raises FY27 adj EPS guidance to $9.21 vs $9.06 est

0 min read | Published on 27 Aug 2026, 01:56 AM |Updated on 27 Aug 2026, 01:56 AM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Veeva Systems raises FY2027 adj EPS guidance to $9.21 from $9.05
New EPS beat of $0.15 over the $9.06 analyst estimate
FY2027 sales guidance lifted to $3.682B-$3.687B range
Previous sales estimate was $3.635B-$3.645B vs $3.645B consensus

*this image is generated using AI for illustrative purposes only.

Veeva Systems (NYSE: VEEV) has raised its full-year guidance for fiscal 2027, lifting both adjusted earnings per share and revenue estimates above analyst expectations.

The clinical trial software provider updated its adjusted EPS outlook for FY2027 to $9.21, up from the previous guidance of $9.05. This new figure exceeds the analyst estimate of $9.06.

Revenue Outlook

Veeva also increased its FY2027 sales guidance range to $3.682 billion-$3.687 billion. The prior range was $3.635 billion-$3.645 billion. The midpoint of the new guidance beats the $3.645 billion analyst estimate.

What the Numbers Show

The upward revision in both top-line and bottom-line metrics indicates stronger-than-anticipated demand or operational efficiency for the period. By raising the floor of its revenue range by approximately $47 million while simultaneously beating EPS estimates, the company signals confidence in maintaining margin expansion alongside growth.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

Which specific segments of Veeva's business, such as Vault or Veeva Network, are driving the stronger-than-anticipated demand for FY2027?

How might this upward revision in guidance influence analyst price targets and institutional investor sentiment for VEEV in the near term?

What operational efficiencies or cost-saving measures is Veeva implementing to sustain margin expansion alongside revenue growth?